AU2022243562A1 - Humanized mab107 - Google Patents

Humanized mab107 Download PDF

Info

Publication number
AU2022243562A1
AU2022243562A1 AU2022243562A AU2022243562A AU2022243562A1 AU 2022243562 A1 AU2022243562 A1 AU 2022243562A1 AU 2022243562 A AU2022243562 A AU 2022243562A AU 2022243562 A AU2022243562 A AU 2022243562A AU 2022243562 A1 AU2022243562 A1 AU 2022243562A1
Authority
AU
Australia
Prior art keywords
seq
antibody
antigen
organ
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2022243562A
Other languages
English (en)
Other versions
AU2022243562A9 (en
Inventor
M. Amin Arnaout
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of AU2022243562A1 publication Critical patent/AU2022243562A1/en
Publication of AU2022243562A9 publication Critical patent/AU2022243562A9/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022243562A 2021-03-26 2022-03-25 Humanized mab107 Abandoned AU2022243562A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163166711P 2021-03-26 2021-03-26
US63/166,711 2021-03-26
PCT/US2022/021950 WO2022204516A1 (en) 2021-03-26 2022-03-25 Humanized mab107

Publications (2)

Publication Number Publication Date
AU2022243562A1 true AU2022243562A1 (en) 2023-10-12
AU2022243562A9 AU2022243562A9 (en) 2024-02-22

Family

ID=83397925

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022243562A Abandoned AU2022243562A1 (en) 2021-03-26 2022-03-25 Humanized mab107

Country Status (7)

Country Link
US (1) US20240158511A1 (https=)
EP (1) EP4313112A4 (https=)
JP (1) JP2024511160A (https=)
CN (1) CN117355322A (https=)
AU (1) AU2022243562A1 (https=)
CA (1) CA3214962A1 (https=)
WO (1) WO2022204516A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026511370A (ja) * 2023-02-27 2026-04-14 カイジーン，インク． ヒト化抗ｃｄ１１ｂ抗体およびその使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399148A1 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US10738121B2 (en) * 2015-02-27 2020-08-11 The General Hospital Corporation Therapeutic use of integrin-binding antibodies
CN107750255B (zh) * 2015-04-17 2022-08-30 安进研发（慕尼黑）股份有限公司 用于cdh3和cd3的双特异性抗体构建体
AU2016274175B2 (en) * 2015-06-12 2021-02-18 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Methods and polypeptides for modulation of immunoresponse

Also Published As

Publication number Publication date
US20240158511A1 (en) 2024-05-16
WO2022204516A1 (en) 2022-09-29
AU2022243562A9 (en) 2024-02-22
JP2024511160A (ja) 2024-03-12
CN117355322A (zh) 2024-01-05
EP4313112A1 (en) 2024-02-07
EP4313112A4 (en) 2025-07-02
CA3214962A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
JP7003348B2 (ja) 糖尿病黄斑浮腫の治療のための組成物および方法
JP6860618B2 (ja) 抗補体Ｃ１ｓ抗体とそれらの用途
JP6259503B2 (ja) 眼疾患の治療
US20230077885A1 (en) Methods for dna-dependent targeting of a cell permeant antibody
TW201525001A (zh) 包含ｎ－端ａｂｐ之單鏈結合分子
CN116648464A (zh) 一种补体抑制剂的开发和应用
US20240158511A1 (en) Humanized mAb107
HK40112454A (zh) Lilrb2特异性单克隆抗体及其使用方法
WO2024022478A1 (zh) 结合大麻素受体cb1的抗体及其用途
NZ623275B2 (en) Treatment of ocular disease

Legal Events

Date Code Title Description
SREP Specification republished
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period